Workflow
MacroGenics, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before September 24, 2024 to Discuss Your Rights - MGNX
MacroGenicsMacroGenics(US:MGNX) Prnewswireยท2024-08-29 09:45

Core Viewpoint - MacroGenics, Inc. (NASDAQ: MGNX) is facing a class action lawsuit due to allegations of material misrepresentations regarding the safety data of its drug vobramitamab duocarmazine during the TAMARACK Phase 2 study, leading to a significant stock decline of 77.4% [1] Group 1 - The class period for the lawsuit is from March 7, 2024, to May 9, 2024 [1] - On May 9, 2024, it was revealed that the drug was significantly more dangerous than previously stated, resulting in a stock price drop of $11.36 per share [1] - Shareholders are encouraged to register for the class action and can do so without any cost or obligation [2] Group 2 - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3] - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3]